RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets

Title:RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets

Volume: 22 Issue: 30

Author(s): Laura de Ramon, Marta Jarque, Elia Ripoll, Oriol Bestard, Josep M. Grinyo and Juan Torras

Affiliation:

Keywords: Ischemia, siRNA, gene silencing, CD40.

Abstract: Background: Ischemia reperfusion injury is an important pathophysiological process in many fields such as transplantation, stroke, atherosclerosis, trauma and myocardial infarction. Recent advances in gene silencing may help to reduce ischemic effects, targeting molecules related to this pathological process. Methods and results: Here, we review the different silencing approaches in ischemic injury, highlighting the role of co-stimulatory molecules in renal transplantation. Conclusion: Gene silencing appears as a new strategy to prevent the inflammation and injury associated with ischemia.

Cite this article as:

de Ramon Laura, Jarque Marta, Ripoll Elia, Bestard Oriol, Grinyo M. Josep and Torras Juan, RNAi-Based Therapy in Experimental Ischemia-Reperfusion Injury. The New Targets, Current Pharmaceutical Design 2016; 22 (30) . https://dx.doi.org/10.2174/1381612822666160719103955